Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Chemotherapy in Metastatic Colorectal Cancer
NCT03193814Phase 2Withdrawn
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in metastatic colorectal cancer (mCRC). Primary endpoint: Progression-free Survival at 2 years. Planned start Dec 2019; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03193814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193814.